Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.
After replacing several management positions over the last year, Poland’s leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-06-17 17:06:002016-06-17 17:06:00Across the blood-brain barrier with ultrasound
Research service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.
https://european-biotechnology.com/wp-content/uploads/2024/04/Nasdaq_GlobeNewswire.png120240h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-06-17 00:00:002016-06-17 00:00:00Pharma finance pro
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-06-16 17:12:002016-06-16 17:12:00Novartis to develop new antimalarial
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-06-14 18:09:092016-06-14 18:09:09Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.
In early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.
Serial founder
AppointmentsManchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
Cat allergy setback for Circassia
Latest NewsCircassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.
Generics visionary
AppointmentsAfter replacing several management positions over the last year, Poland’s leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.
Across the blood-brain barrier with ultrasound
Latest NewsCarThera’s ultrasound device opens a gate for therapeutic molecules into the brain, study shows.
Pharma finance pro
AppointmentsResearch service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.
Novartis to develop new antimalarial
Latest NewsWith support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.
Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
Sponsored PublicationsGilde closes €250m growth fund
Latest NewsEuropean specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.
Oncology expert
AppointmentsIn early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.
Auditing matters
AppointmentsDutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQure’s Audit Committee.